Supplementary Data Figure S1 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Year: 2023
Type: supplementary-materials
Abstract: Amino acid sequence of the antibody used in ARX788. The complementarity determining regions (CDRs) are underlined, and the pAF is depicted as a "U".
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362489736